Avacta Group Plc (AVCT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Avacta Group Plc (AVCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12337
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products that include optim and sensipod. It also develops UCB celltech that is an analytical instrument. Avacta’s sensipod is an in-clinical blood testing system that delivers ELISA tests. The company offers intellectual property relating to an alternative to antibodies. It develops reagents and diagnostics that are used in affinity chromatography, protein to protein interactions, immunoassay and rapid diagnostic test applications, among others. It has operations in Wetherby, Cambridge and London. Avacta is headquartered in Wetherby, the UK.

Avacta Group Plc (AVCT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Avacta Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Avacta Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Avacta Group Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Avacta Group Enters into Co-Development Agreement with Tufts University 12
Avacta Enters into Research Agreement with OncoSec Medical 13
Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 14
Avacta Enters into Agreement with Glythera 15
Avacta Enters into Research Agreement with University of Leeds 16
Avacta Enters Into Agreement With UbiQ Bio For Ubiquitin Affimers 17
Avacta Life Sciences Enters Into Co-Development Agreement With University of Liverpool 18
Licensing Agreements 19
Avacta Enters into Licensing Agreement with Glythera 19
Moderna Therapeutics Enters into Licensing Agreement with Avacta Life Sciences 20
Avacta Enters Into Licensing Agreement With Blueberry Therapeutics For Affimers 21
Equity Offering 22
Avacta Group Raises USD15.2 Million in Private Placement of Shares 22
Avacta Announces Private Placement Of Shares For US$17 Million 23
Asset Transactions 25
Unchained Labs Acquires Optim Technology from Avacta for USD5 Million 25
Acquisition 26
Avacta Group Completes Acquisition Of Biotech Company Aptuscan For US$2.3 Million 26
Avacta Group Plc – Key Competitors 27
Avacta Group Plc – Key Employees 28
Avacta Group Plc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Oct 02, 2018: Avacta Group: Preliminary results for the year ending 31 July 2018 31
Apr 16, 2018: Avacta Group Announces Interim Results for the Period Ended 31 January 2018 44
Oct 04, 2017: Avacta Group: Preliminary Results for the Year Ending 31 July 2017 50
Aug 07, 2017: Avacta Group: Trading Update and Notice of Results 51
Apr 03, 2017: Avacta Group: Interim results for the period ended 31 January 2017 53
Corporate Communications 54
Jun 11, 2018: Avacta Group Appointments Dr Eliot Forster As Non-Executive Chairman 54
Mar 29, 2018: Avacta Group Announces Directorate Change 55
Government and Public Interest 56
Jan 20, 2017: AGM business update and notice of results 56
Other Significant Developments 57
Jan 18, 2018: Avacta Group: AGM Business Update and Notice of Results 57
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Avacta Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Avacta Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Avacta Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Avacta Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Avacta Group Enters into Co-Development Agreement with Tufts University 12
Avacta Enters into Research Agreement with OncoSec Medical 13
Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 14
Avacta Enters into Agreement with Glythera 15
Avacta Enters into Research Agreement with University of Leeds 16
Avacta Enters Into Agreement With UbiQ Bio For Ubiquitin Affimers 17
Avacta Life Sciences Enters Into Co-Development Agreement With University of Liverpool 18
Avacta Enters into Licensing Agreement with Glythera 19
Moderna Therapeutics Enters into Licensing Agreement with Avacta Life Sciences 20
Avacta Enters Into Licensing Agreement With Blueberry Therapeutics For Affimers 21
Avacta Group Raises USD15.2 Million in Private Placement of Shares 22
Avacta Announces Private Placement Of Shares For US$17 Million 23
Unchained Labs Acquires Optim Technology from Avacta for USD5 Million 25
Avacta Group Completes Acquisition Of Biotech Company Aptuscan For US$2.3 Million 26
Avacta Group Plc, Key Competitors 27
Avacta Group Plc, Key Employees 28
Avacta Group Plc, Other Locations 29
Avacta Group Plc, Subsidiaries 29

List of Figures
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Avacta Group Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Avacta Group Plc (AVCT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nordic Nanovector ASA (NANO):企業の財務・戦略的SWOT分析
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of hematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for …
  • Nobel Biocare Services AG:企業の製品パイプライン分析
    Summary Nobel Biocare Services AG (Nobel Biocare), a subsidiary of Danaher Corporation, is a provider of implant-based dental restorations. The company offers various solutions, including dental implant systems; high-precision individualized prosthetics; CAD/CAM systems; diagnostics and treatment pl …
  • Blue Energy Ltd (BUL):石油・ガス:M&Aディール及び事業提携情報
    Summary Blue Energy Ltd (BEL) is an oil and gas company that provides exploration and development services. The company provides exploration and production of coal seam gas and conventional oil, and gas resources in Australia. Its projects portfolio includes carpentaria basin, bowen basin, galilee b …
  • Nexus AG (NXU):企業の財務・戦略的SWOT分析
    Summary Nexus AG (Nexus) is a healthcare technology company that provides healthcare software solutions. The company provides products such as NEXUS and HIS, a hospital information system; NEXUS and DIS, a special ward and department solutions; and NEXUS and QM, a solution in quality management, amo …
  • Marubun Corporation:企業の戦略・SWOT・財務分析
    Marubun Corporation - Strategy, SWOT and Corporate Finance Report Summary Marubun Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Humana Inc (HUM)-医療機器分野:企業M&A・提携分析
    Summary Humana Inc (Humana) is a health and well-being company that offers health insurance and Medicare plans, insurance products, and health and wellness services to healthcare providers, employers, individuals, administrators, government, and the public sector. The company’s Medicare products and …
  • Energias de Portugal SA (EDP)-石油・ガス分野:企業M&A・提携分析
    Summary Energias de Portugal, S.A. (EDP) is a vertically integrated power and gas utility that generates, transmits, distributes and sells electricity; and transports, distributes and sells natural gas. It produces electricity through a diversified portfolio of generation assets including wind, sola …
  • UTStarcom Holdings Corp. (UTSI):企業の財務・戦略的SWOT分析
    UTStarcom Holdings Corp. (UTSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Savencia SA:企業の戦略・SWOT・財務情報
    Savencia SA - Strategy, SWOT and Corporate Finance Report Summary Savencia SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • University of Arizona-製薬・医療分野:企業M&A・提携分析
    Summary University of Arizona (UA) is a healthcare research university that offers undergraduate and graduate degrees. The university’s academic departments include cancer biology graduate interdisciplinary program, cancer biology, cellular and molecular medicine, cancer center, center for education …
  • Mercer LLC:企業の戦略的SWOT分析
    Mercer LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • HUYA Bioscience International LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary HUYA Bioscience International LLC (HUYA) is a biopharmaceutical company that develops early and late-stage drug candidates. The company’s pipeline products include HBI-8000, HBI-3000, and HBI-3802. Its HBI-8000 is a novel oral inhibitor of histone deacetylases; HBI-3000 is a channel blocker …
  • Industrial Bank Of Korea:企業の戦略・SWOT・財務分析
    Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sichuan Kelun Pharmaceutical Co Ltd (002422)-製薬・医療分野:企業M&A・提携分析
    Summary Sichuan Kelun Pharmaceutical Co Ltd (Kelun) is a pharmaceutical company that manufactures and distributes IV Solutions. The company’s products include mannitol injection, glucose injection, sodium chloride injection, glucose and sodium chloride injection, ringer’s injection, lactated ringer’ …
  • RPC Group PLC:企業のM&A・事業提携・投資動向
    RPC Group PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's RPC Group PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Forum Energy Technologies, Inc.:戦略・SWOT・企業財務分析
    Forum Energy Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Forum Energy Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cerner Corp (CERN):企業の財務・戦略的SWOT分析
    Cerner Corp (CERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Orkuveita Reykjavikur-エネルギー分野:企業M&A・提携分析
    Summary Orkuveita Reykjavikur (Orkuveita) is a public utility company that provides electricity and water. The company generates and supplies electricity. It harnesses hot water from geothermal fields and supplies it for heating applications. The company also supplies cold water from its groundwater …
  • CRISPR Therapeutics:戦略・SWOT・企業財務分析
    CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report Summary CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Immucor, Inc.:企業の戦略的SWOT分析
    Immucor, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆